| Year |
Citation |
Score |
| 2019 |
Shehadeh J, Double KL, Murphy KE, Bobrovskaya L, Reyes S, Dunkley PR, Halliday GM, Dickson PW. Expression of tyrosine hydroxylase isoforms and phosphorylation at serine 40 in the human nigrostriatal system in Parkinson's disease. Neurobiology of Disease. 104524. PMID 31276794 DOI: 10.1016/j.nbd.2019.104524 |
0.316 |
|
| 2014 |
Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, Thompson L, Halliday G, Kirik D. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain : a Journal of Neurology. 137: 2493-508. PMID 25062696 DOI: 10.1093/Brain/Awu193 |
0.335 |
|
| 2013 |
Reyes S, Cottam V, Kirik D, Double KL, Halliday GM. Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1351-9. PMID 23674405 DOI: 10.1002/Mds.25493 |
0.315 |
|
| 2013 |
Reyes S, Fu Y, Double KL, Cottam V, Thompson LH, Kirik D, Paxinos G, Watson C, Cooper HM, Halliday GM. Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. Neurobiology of Aging. 34: 873-86. PMID 22926168 DOI: 10.1016/J.Neurobiolaging.2012.07.019 |
0.32 |
|
| 2012 |
Reyes S, Fu Y, Double K, Thompson L, Kirik D, Paxinos G, Halliday GM. GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. The Journal of Comparative Neurology. 520: 2591-607. PMID 22252428 DOI: 10.1002/Cne.23051 |
0.331 |
|
| 2012 |
Double KL. Neuronal vulnerability in Parkinson's disease. Parkinsonism & Related Disorders. 18: S52-4. PMID 22166454 DOI: 10.1016/S1353-8020(11)70018-9 |
0.326 |
|
| 2010 |
Double KL, Reyes S, Werry EL, Halliday GM. Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Progress in Neurobiology. 92: 316-29. PMID 20541584 DOI: 10.1016/j.pneurobio.2010.06.001 |
0.319 |
|
| 2006 |
Double KL, Halliday GM. New face of neuromelanin. Journal of Neural Transmission. Supplementum. 119-23. PMID 17017518 |
0.316 |
|
| 2005 |
Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Progress in Neurobiology. 75: 109-24. PMID 15784302 DOI: 10.1016/j.pneurobio.2005.02.001 |
0.331 |
|
| 2004 |
Götz ME, Double K, Gerlach M, Youdim MBH, Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease Annals of the New York Academy of Sciences. 1012: 193-208. PMID 15105267 DOI: 10.1196/annals.1306.017 |
0.338 |
|
| 2003 |
Double KL, Halliday GM, Henderson J, Griffiths FM, Heinemann T, Riederer P, Gerlach M. The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. Experimental Neurology. 184: 530-5. PMID 14637122 DOI: 10.1016/J.Expneurol.2003.08.006 |
0.303 |
|
| 2003 |
Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. Dopamine receptor agonists in current clinical use: Comparative dopamine receptor binding profiles defined in the human striatum Journal of Neural Transmission. 110: 1119-1127. PMID 14523624 DOI: 10.1007/S00702-003-0027-5 |
0.308 |
|
| 2003 |
Gerlach M, Double K, Reichmann H, Riederer P. Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease Journal of Neural Transmission, Supplement. 167-183. PMID 12946055 DOI: 10.1007/978-3-7091-0643-3_10 |
0.326 |
|
| 2000 |
Xiao AY, Double K, Heinemann T, Rausch WD, Riederer P, Gerlach M. The industrial chemical Tinuvin 123 does not induce dopaminergic neurotoxicity in C57Bl/6 mice Neuroscience Letters. 278: 165-168. PMID 10653019 DOI: 10.1016/S0304-3940(99)00933-7 |
0.33 |
|
| Show low-probability matches. |